secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001213900-24-097894
Event type: earnings
Sentiment:  positive
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma Q3 revenue $389K, net loss narrows to $134K; first operational profit
--------------------------------------------------------------------------------

- Revenue of $389,276 in Q3 2024 vs $15,884 in Q3 2023, a 2,350% increase.
- Net loss narrowed to $134,272 from $3.37M; EPS improved to -$0.02 from -$0.82.
- Cash balance grew to $137,344 vs $60,155 at year-end 2023.
- Achieved first operational profit but higher interest from convertible debt kept EPS negative.
- Licensing agreements could provide up to $292 million; $496K milestone cash received in 9 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/0001213900-24-097894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/ea0221143-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-097894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer